Literature DB >> 17613709

Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India.

Jayashree Das Gupta1, P Satishchandra, Kumarpillai Gopukumar, Frances Wilkie, Drenna Waldrop-Valverde, Ronald Ellis, Raymond Ownby, D K Subbakrishna, Anita Desai, Anupa Kamat, V Ravi, B S Rao, K S Satish, Mahendra Kumar.   

Abstract

Most studies of cognitive functioning in human immunodeficiency virus type 1 (HIV-1)-seropositive (HIV-1+) subjects have been done in the United States and Europe, where clade B infections predominate. However, in other parts of the world such as South India, where clade C HIV is most common, the prevalence of HIV-1 is increasing. Standardized neuropsychological tests were used to assess cognitive functioning in a sample of 119 adults infected with clade C HIV-1 who were not on antiretroviral medications. The subjects did not have neurological or psychiatric illness and were functioning adequately. Neuropsychological test performance was compared with gender-, age-, and education-matched normative data derived from a sample of 540 healthy volunteers and a matched cohort of 126 healthy, HIV-1-seronegative individuals. Among the seropositive subjects, 60.5% had mild to moderate cognitive deficits characterized by deficits in the domains of fluency, working memory, and learning and memory. None of the subjects had severe cognitive deficits. The HIV-1+ sample was classified into groups according to the level of immune suppression as defined by CD4 count (< 200, 201-499, and > 500 cells/mm3) and viral load (< 5000, 5001-30,000, 30,001-99,999, 100,000-1,000,000, and > 1,000,001 copies). Although the most immunosuppressed group (CD4 count < 200 cells/mm3 or viral load > 1,000,001 copies) was small, their rate of impairment in visual working memory was greater when compared to groups with better immune functioning. Mild to moderate cognitive deficits can be identified on standardized neuropsychological tests in clade C-infected HIV-1+ adults who do not have any clinically identifiable functional impairment. The prevalence of cognitive deficits is similar to that reported in antiretroviral treatment-naïve individuals infected with clade B virus in the western world.

Entities:  

Mesh:

Year:  2007        PMID: 17613709     DOI: 10.1080/13550280701258407

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  32 in total

1.  Neurobehavioral functioning in a nonconfounded group of asymptomatic HIV-seropositive homosexual men.

Authors:  R A Stern; N G Singer; S G Silva; H J Rogers; D O Perkins; C D Hall; C M van der Horst; D L Evans
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

2.  Verbal working memory storage and processing deficits in HIV-1 asymptomatic and symptomatic individuals.

Authors:  M K York; J J Franks; R R Henry; W J Hamilton
Journal:  Psychol Med       Date:  2001-10       Impact factor: 7.723

3.  Verbal and spatial working memory performance among HIV-infected adults.

Authors:  Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Mona N Lam; Marta Stefaniak; Bryan Zolnikov
Journal:  J Int Neuropsychol Soc       Date:  2002-05       Impact factor: 2.892

4.  Neurological manifestations of HIV disease.

Authors:  R S Wadia; S N Pujari; S Kothari; M Udhar; S Kulkarni; S Bhagat; A Nanivadekar
Journal:  J Assoc Physicians India       Date:  2001-03

5.  Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads--a study from South India.

Authors:  Prabha S Chandra; Charu Gandhi; P Satishchandra; Anupa Kamat; Anita Desai; V Ravi; Raymond L Ownby; D K Subbakrishna; Mahendra Kumar
Journal:  Qual Life Res       Date:  2006-10-11       Impact factor: 4.147

6.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

7.  Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  R K Heaton; R A Velin; J A McCutchan; S J Gulevich; J H Atkinson; M R Wallace; H P Godfrey; D A Kirson; I Grant
Journal:  Psychosom Med       Date:  1994 Jan-Feb       Impact factor: 4.312

8.  WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings.

Authors:  M Maj; P Satz; R Janssen; M Zaudig; F Starace; L D'Elia; B Sughondhabirom; M Mussa; D Naber; D Ndetei
Journal:  Arch Gen Psychiatry       Date:  1994-01

9.  ERPs differ from neurometric tests in assessing HIV-associated cognitive deficit.

Authors:  Jaime L Tartar; Colleen M Sheehan; Allan J Nash; Christopher Starratt; Ana Puga; Susan Widmayer
Journal:  Neuroreport       Date:  2004-07-19       Impact factor: 1.837

10.  Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India.

Authors:  Nagadenahalli B Siddappa; Prashanta K Dash; Anita Mahadevan; Narayana Jayasuryan; Fen Hu; Bethany Dice; Randy Keefe; Kadappa S Satish; Bhuthiah Satish; Kuttan Sreekanthan; Ramdas Chatterjee; Kandala Venu; Parthasarathy Satishchandra; Vasanthapuram Ravi; Susarla K Shankar; Raj Shankarappa; Udaykumar Ranga
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

View more
  63 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

Review 2.  NeuroAIDS in Africa.

Authors:  Kevin Robertson; Jeff Liner; James Hakim; Jean-Louis Sankalé; Igor Grant; Scott Letendre; David Clifford; Amadou Gallo Diop; Assan Jaye; Georgette Kanmogne; Alfred Njamnshi; T Dianne Langford; Tufa Gemechu Weyessa; Charles Wood; Mwanza Banda; Mina Hosseinipour; Ned Sacktor; Noeline Nakasuja; Paul Bangirana; Robert Paul; John Joska; Joseph Wong; Michael Boivin; Penny Holding; Betsy Kammerer; Annelies Van Rie; Prudence Ive; Avindra Nath; Kathy Lawler; Clement Adebamowo; Walter Royal; Jeymohan Joseph
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

3.  Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Francisco Jaime Barbosa; Rujvi Kamat; Ana Paula de Pereira; Sonia Mara Raboni; Indianara Rotta; Clea Elisa Ribeiro; Mariana Cherner; Ronald J Ellis; Joseph Hampton Atkinson
Journal:  J Neurovirol       Date:  2016-07-18       Impact factor: 2.643

4.  Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins.

Authors:  Grant R Campbell; Jennifer D Watkins; Erwann P Loret; Stephen A Spector
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-07       Impact factor: 2.205

Review 5.  Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders.

Authors:  Suman Jayadev; Gwenn A Garden
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-17       Impact factor: 4.147

6.  Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.

Authors:  Norma Kabuba; J Anitha Menon; Donald R Franklin; Robert K Heaton; Knut A Hestad
Journal:  AIDS Behav       Date:  2017-06

7.  Chronic HIV-1 Tat and HIV reduce Rbfox3/NeuN: evidence for sex-related effects.

Authors:  Yun Kyung Hahn; Ruturaj R Masvekar; Ruqiang Xu; Kurt F Hauser; Pamela E Knapp
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

8.  Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study.

Authors:  Wadchara Pumpradit; Jintanat Ananworanich; Sermsak Lolak; Cecilia Shikuma; Robert Paul; Umaporn Siangphoe; Nithima Chaoniti; Peeraporn Kaew-On; Robert Paris; Kiat Ruxrungtham; Victor Valcour
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

9.  Neuronal toxicity in HIV CNS disease.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Future Virol       Date:  2012-07-01       Impact factor: 1.831

10.  HIV-1 clade-specific differences in the induction of neuropathogenesis.

Authors:  Vasudev R Rao; Andrew R Sas; Eliseo A Eugenin; Nagadenahalli B Siddappa; Heather Bimonte-Nelson; Joan W Berman; Udaykumar Ranga; William R Tyor; Vinayaka R Prasad
Journal:  J Neurosci       Date:  2008-10-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.